Sun Pharma’s US subsidiaries have agreed to pay out $85m to settle US antitrust litigation over generic price-fixing with direct purchaser plaintiffs.
Sun Pharma has announced that its US subsidiaries Taro Pharmaceuticals USA and Sun Pharmaceutical Industries Inc. have struck a deal that will see the pair pay out $85m to settle generic price-fixing allegations.
Sun and Taro “have signed settlement agreements with the direct purchaser plaintiffs in the generic pharmaceuticals pricing antitrust litigation that has been taking place in the Eastern District of Pennsylvania,
Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”
Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.
Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.
Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.
